Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz
National Institute of Allergy and Infectious Diseases (NIAID)
This study will continue to treat and collect safety and efficacy data on patients who
participated in Glaxo-Wellcome's multi-center study on combination therapy with abacavir,
amprenavir and efavirenz (A Phase II Study Evaluating the Safety and Antiviral Activity of
Combination Therapy with 1592U89, 141W94 and DMP 266 (Sustiva) in HIV-1 Infected Subjects
with Detectable [greater than 400 Copies/mL] HIV-1 Plasma RNA Despite Treatment with a
Protease Inhibitor-Containing Regimen).
HIV-infected patients 18 years of age and older who participated in the above study at the
NIH site may be eligible for the current study. Participants will be followed every 3 months
with a general health evaluation and laboratory tests. This is a NIH study, and information
will not be provided to Glaxo Wellcome
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.